drugset / Trial / NCT03481036
DAA Therapy in Pediatric Patients With Chronic Hepatitis C
Unknown
100 enrolled
Post Graduate Institute of Medical Education and Research, Chandigarh
Directorate of Health and Family Welfare, Punjab · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The Mukh-Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) is a public health initiative for prevention and control of hepatitis C in the Punjab state, India. The efficacy of decentralised public health services and safety of 12- or 24-weeks of sofosbuvir (SOF) + ledipasvir (LDV) or SOF + daclatasvir (DCV) with or without ribavirin (RBV) in the treatment of pediatric chronic hepatitis C will be assessed
Timeline
- Start
- 2016-06-18
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclatasvir | Small molecule | 30 mg | — |
| Comparator | Daclatasvir | Small molecule | 60 mg | — |
| Comparator | Ledipasvir | Small molecule | 45 mg | — |
| Comparator | Ledipasvir | Small molecule | 90 mg | — |
| Comparator | Ribavirin | Small molecule | — | — |
| Comparator | Sofosbuvir | Small molecule | 200 mg | — |
| Comparator | Sofosbuvir | Small molecule | 400 mg | — |